Positive outlook for AstraZeneca’s Fasenra in asthma

UK pharma major AstraZeneca’s (LSE: AZN) Fasenra (benralizumab) recently received Food and Drug Administration (FDA) approval for severe asthma in children aged six to 11, specifically for the eosinophilic phenotype, in over 80 countries, including the USA, European Union, and Japan.

Fasenra is a monoclonal antibody intended to inhibit the alpha subunit of the interleukin-5 receptor found on eosinophils and is currently a Phase III clinical trial agent for chronic obstructive pulmonary disease (COPD) treatment. A current gap in the COPD market is the absence of biologics, however, Fasenra has the potential to address this gap, says pharma analytics company GlobalData.

According to GlobalData’s Sales and Forecast database, total sales for Fasenra are forecast to reach $2.0 billion globally by 2029. AstraZeneca’s Fasenra is one of the six late-stage biologics being developed for COPD, alongside its tozorakimab (Phase III) and Tezspire (Phase II).